Article

Laser bests injections for CSC

Photocoagulation performed using a micropulse subthreshold diode laser (MicroPulse, Iridex) was superior to intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy, according to a comparative, controlled, prospective study.

Mountain View, CA-Photocoagulation performed using a micropulse subthreshold diode laser (MicroPulse, Iridex) was superior to intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy (CSC), according to a comparative, controlled, prospective study.

The results of the study were announced by Iridex.

The 10-month study examined 52 eyes of 52 patients treated with either the laser at the active leakage site (16 eyes), intravitreal injection of 1.25 mg bevacizumab (10 eyes), or observation (26 eyes). Outcome measures included changes in retinal pigment epithelium, central macular thickness, best-corrected visual acuity, and 10º macular perimetry.

This was the first comparative, prospective evaluation of subthreshold diode laser treatment and anti-vascular endothelial growth factor (VEGF) injections in the treatment of CSC with regard to changes in subretinal fluid and visual function. The results indicated superior subretinal fluid resolution and superior improvement in visual acuity and other visual functions in patients who received the laser treatment compared with those who received the anti-VEGF injections.

“Because of the absence of laser-induced retinal damage discernable at any time postoperatively, [micropulse subthreshold diode laser] photocoagulation, with no focal burn end point (or its consequences), represents an elegant medical approach and a true clinical alternative,” said co-author Frank Koch, MD, who oversees the vitreo-retinal department at the University Eye Clinic of Johann Wolfgang Goethe-University, Frankfurt, Germany.

“[The laser] therapy is producing the kind of clinical results that we believe will fuel a paradigm shift in the treatment of retinal diseases,” added Dominik Beck, PhD, Iridex president and chief executive officer. “While CSC does not [affect] a large population, this study is additional clinical evidence of the efficacy and safety in using [micropulse subthreshold diode laser] therapy to treat a broader class of retinal diseases that impacts millions of Americans.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
© 2025 MJH Life Sciences

All rights reserved.